Search results for "Neoplastic"

showing 10 items of 2901 documents

Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy.

2009

Objective. To analyze medication errors (MEs) in a multidisciplinary system with a Computerized Pharmacotherapy Process (CPP) in cancer patients. Design. A longitudinal, prospective 2-year (January 2003 —to December 2004) cohort study was made in adult patients administered antineoplastic treatment in Services of Oncology and Haematology. MEs were identified by double cross-validation of each stage of the pharmacotherapeutic process (prescription, preparation, dispensing, administration, and follow-up) carried out by the multidisciplinary team (physician, pharmacist, nurse) with CPP assistance. Variables. Number of MEs per 1000 patient-days, percentage according to the stage of the pharmac…

medicine.medical_specialtyMedication Systems Hospitalanimal structuresInterprofessional RelationsPharmacistNursesAntineoplastic AgentsPharmacistsCohort StudiesHospitals UniversityPharmacotherapyMultidisciplinary approachAntineoplastic chemotherapyPhysiciansmedicineHumansMedication ErrorsPharmacology (medical)Longitudinal StudiesProspective StudiesMedical prescriptionStage (cooking)Adult patientsbusiness.industrySurgeryOncologyEmergency medicinebusinessCohort studyFollow-Up StudiesJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

CT and MR Imaging of Non-neoplastic Intracranial Masses

1989

Many intracranial mass lesions of non-neoplastic origin present CT and MR features similar or identical to those of true neoplasms. In many cases a definitive diagnosis cannot be made from imaging findings alone, and misinterpretation is possible even when the history and clinical findings are considered. Yet an accurate preoperative diagnosis is an essential prerequisite for selecting candidates for a neurosurgical operation and planning the procedure. In some cases the full range of neuroradiologic techniques may have to be applied and evaluated in the context of clinical findings before the physician can accurately classify the disease and draw appropriate therapeutic conclusions.

medicine.medical_specialtyNon neoplasticbusiness.industryProgressive multifocal leukoencephalopathyPrimary central nervous system lymphomaContext (language use)medicine.diseaseMr imagingArachnoid cystmedicineRadiologybusinessBrain abscessIntracranial mass
researchProduct

Correlates of hormone replacement therapy use in Italian women, 1992-1996

1999

we analyzed the determinants of hormonal replacement therapy (HRT) use in Italy for the period 1992-1996, using data from a framework of case-control studies of colon and rectal neoplasm.a total of 1574 women aged 45-74 years were considered. This group comprised women with acute, non neoplastic, non-hormone-related diseases admitted to a network of hospitals in six areas of Italy.a total of 146 women (8.5%) reported ever HRT use. The multivariate odds ratio (OR) of ever use was 1.6 (95% CI 1.0-2.6) for women with 12 years of education or more, compared with those with7 years. The frequency of use of HRT tended to decrease with increasing parity: the OR was 0.6 for women with four or more c…

medicine.medical_specialtyNon neoplasticmenopauseGeneral Biochemistry Genetics and Molecular BiologyInternal medicineRectal NeoplasmmedicineHumansSocioeconomic statusAgedClimactericGynecologybusiness.industryEstrogen Replacement TherapyHormonal replacement therapyObstetrics and GynecologyOdds ratiocase control studyMiddle AgedPatient Acceptance of Health CareHormone replacement therapyItalyTransgender hormone therapyHormone replacement therapy; case control study; menopauseFemalebusinessHuman
researchProduct

Obstetric and offspring risks of women’s morbid conditions linked to prior anticancer treatments

2016

Background Literature shows the effects of type of cancer and/or anticancer treatment on live birth percentages and/or pregnancy and neonatal complications in female cancer survivors. However, studies analyzing the obstetric and offspring risks of the morbid conditions associated with previous anti-cancer treatments are missing. The present review aims to uncover these risks. Methods A literature search based on publications up to March 2016 identified by PubMed and references cited in relevant articles. Results The morbid conditions associated with prior anticancer treatments including chemotherapy, radiotherapy, surgery, and/or hematopoietic stem-cell transplant may induce not only obstet…

medicine.medical_specialtyOffspringmedia_common.quotation_subjectReproductive medicineAntineoplastic AgentsFertilityReview03 medical and health sciences0302 clinical medicineEndocrinologyPregnancyRisk FactorsNeoplasmsmedicineHumansProspective StudiesProspective cohort studymedia_commonPregnancy030219 obstetrics & reproductive medicineRadiotherapyObstetricsbusiness.industryHematopoietic Stem Cell TransplantationObstetrics and GynecologyCancerDelivery Obstetricmedicine.diseaseFertilityTreatment OutcomePregnancy complicationsReproductive MedicineGynecologyPrenatal Exposure Delayed Effects030220 oncology & carcinogenesisGestationFemalebusinessLive birthGestationDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and I.V. 5-fluorouracil (5-FU) chemotherapy for unresectable co…

1991

Several phase III clinical trials demonstrated that hepatic arterial chemotherapy for unresectable colorectal liver metastases is able to provide significantly higher response rates than those obtained by systemic route: in more than 500 patients collected from 6 randomized trials, the median values of objective response rates were 55% after fluoxuridine (FUdR) continuous hepatic arterial infusion (HAI) vs. 18.5% after FUdR or 5-fluorouracil (5-FU) intravenous (i.v.) chemotherapy. Furthermore, the majority of those studies reported that median survival increased in the patient subgroups treated with intrahepatic chemotherapy, even if not always statistically significant [1-6]. Certainly, FU…

medicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchRectumGastroenterologyMetastasisHepatic arterial infusionInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialCisplatinChemotherapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateClinical trialmedicine.anatomical_structureOncologyFluorouracilDrug EvaluationSurgeryFluorouracilColorectal NeoplasmsFloxuridinebusinessmedicine.drugJournal of Surgical Oncology
researchProduct

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A. Okines, M. Verheij, W. Allum, D. Cunningham & A. Cervantes On behalf of the ESMO Guidelines Working Group* GI Clinical Trials Unit, Royal Marsden Hospital, Sutton, UK; Department of Radiation Oncology and Division of Cellular Biochemistry, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgery, Royal Marsden Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton, UK; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

medicine.medical_specialtyPalliative careTreatment outcomeMeta-Analysis as TopicStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsGastroscopyRadiation oncologyEpidemiologymedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicRadiotherapybusiness.industryIncidenceGeneral surgeryPalliative CareCancerHematologymedicine.diseaseCombined Modality TherapySurvival AnalysishumanitiesSurgeryEuropeClinical PracticeTreatment OutcomeOncologyClinical trials unitDiagnosis treatmentChemotherapy AdjuvantbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy

2005

Background: Mouse models of colitis and cancer are indispensable for our understanding of the pathogenesis of these diseases. In the past, mice had to be sacrificed in order to analyse colitis activity and tumour development. We have developed a safe method for high resolution endoscopic monitoring of living mice. Methods: Mice developing colitis or colonic tumours were anaesthetised using avertine and repeatedly examined by endoscopy. A novel miniendoscope (1.9 mm outer diameter), denoted Coloview, was introduced via the anus and the colon was carefully insufflated with an air pump before analysis of the colonic mucosa. An extra working channel allowed the introduction of biopsy forceps or…

medicine.medical_specialtyPathologyColorectal cancerAzoxymethaneColonoscopyMice Inbred StrainsSeverity of Illness IndexGastroenterologyChromoendoscopyMiceIntestinal mucosaInternal medicineBiopsymedicineAnimalsIntestinal MucosaColitisGrading (tumors)Colonoscopesmedicine.diagnostic_testbusiness.industryDextran SulfateInflammatory Bowel DiseaseGastroenterologyCancerColonoscopyColitismedicine.diseaseDisease Models AnimalCell Transformation NeoplasticColonic NeoplasmsDisease ProgressionbusinessGut
researchProduct

Iatrogenic pulmonary lesions.

2018

Treatment of patients often includes the administration of medications and sometimes radiation. While the intent is to treat an underlying condition, in some cases, adverse effects occur due to these agents. Most of these adverse effects are mild, however, some can be severe and life-threatening. Furthermore, while these effects are often reversible upon cessation of exposure, especially if the inciting agent is recognized and withdrawn early, others might be permanent or even progressing. Most common histopathologic findings in drug-induced interstitial lung disease include nonspecific interstitial pneumonia (cellular and/or fibrotic), organizing pneumonia with or without bronchiolitis, eo…

medicine.medical_specialtyPathologyDrug-Related Side Effects and Adverse ReactionsPolymersIatrogenic DiseaseAmiodaroneAntineoplastic Agents030204 cardiovascular system & hematologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineEarly Medical InterventionmedicineEosinophilic pneumoniaHumansImmunologic FactorsIntensive care medicineDiffuse alveolar damageAdverse effectLungLungRadiotherapybusiness.industryInterstitial lung diseasePulmonary edemamedicine.diseasemedicine.anatomical_structureEquipment and SuppliesNitrofurantoin030220 oncology & carcinogenesisPulmonary hemorrhagebusinessLung Diseases InterstitialAnti-Arrhythmia AgentsHydrophobic and Hydrophilic InteractionsHypersensitivity pneumonitisSeminars in diagnostic pathology
researchProduct

Expression of Cytokeratin 7 and 20 in Pathological Conditions of the Bile Tract

2003

Expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) helps to establish the origin of biliary and metastatic carcinomas. We investigated the expression of CK7 and CK20 in inflammatory, metaplastic and neoplastic conditions of the bile ducts, and evaluated possible relationships between the CK expression pattern and extrahepatic bile duct/gallbladder carcinomas (EBDCs) or intrahepatic bile duct carcinomas (IBDCs). We used immunohistochemistry for the investigation of 48 formalin-fixed, paraffin-embedded specimens grouped as: A) lithiasic or inflamed surgically resected extrahepatic bile ducts/gallbladders: all were CK7+/CK20+; B) percutaneous liver biopsies from patients with chronic …

medicine.medical_specialtyPathologyIntestinal metaplasia2734Intrahepatic bile ductsBile duct tumors; Cytokeratin 20 (CK20); Cytokeratin 7 (CK7); Intestinal metaplasia; Bile Duct Diseases; Bile Duct Neoplasms; Bile Ducts Extrahepatic; Bile Ducts Intrahepatic; Carcinoma; Cell Transformation Neoplastic; Gallbladder Diseases; Gallbladder Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Intermediate Filament Proteins; Keratin-20; Keratin-7; Keratins; 2734Bile Duct DiseasesGallbladder DiseasesKeratin-20Settore MED/08 - Anatomia PatologicaGastroenterologyIntermediate Filament ProteinPathology and Forensic MedicinePrimary sclerosing cholangitisCytokeratinPrimary biliary cirrhosisIntermediate Filament ProteinsBile Ducts ExtrahepaticInternal medicineBile duct tumormedicineHumansCytokeratin 7 (CK7)Bile Duct NeoplasmGallbladder NeoplasmBile ductbusiness.industryGene Expression ProfilingGallbladderKeratin 20CarcinomaGallbladder DiseaseKeratin-7Bile Duct DiseaseCell Biologymedicine.diseaseImmunohistochemistryBile Ducts IntrahepaticCell Transformation Neoplasticmedicine.anatomical_structureBile Duct NeoplasmsKeratinKeratin 7KeratinsGallbladder NeoplasmsbusinessCytokeratin 20 (CK20)HumanPathology - Research and Practice
researchProduct

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases

1995

The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the first patient showed an early recurrence at distant sites, which required systemic cytotoxic chemotherapy. The patient with uterine non-Hodgkin lymphoma received a…

medicine.medical_specialtyPathologyWorking Formulationmedicine.medical_treatmentMammary glandUterusBreast NeoplasmsCHOPimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadical surgeryChemotherapybusiness.industryLymphoma Non-HodgkinGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyLymphomaRadiation therapymedicine.anatomical_structureOncologyUterine NeoplasmsFemaleSurgeryLymphoma Large B-Cell DiffuseRadiologybusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct